Severity: Warning
Message: fopen(/var/cpanel/php/sessions/ea-php74/ci_session051a262b94bfc855b79219682032042b1a6e64d3): failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 176
Backtrace:
File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 9
Function: __construct
File: /home/drugtodayonline/public_html/index.php
Line: 311
Function: require_once
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/cpanel/php/sessions/ea-php74)
Filename: Session/Session.php
Line Number: 143
Backtrace:
File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 9
Function: __construct
File: /home/drugtodayonline/public_html/index.php
Line: 311
Function: require_once
Glenmark, Lotus International collaborate to commercialise Ryaltris nasal spray in Singapore
DTMT Network
Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals, has entered into an exclusive licensing agreement with Lotus International, a wholly-owned subsidiary of Lotus Pharmaceutical Co., Ltd. (Lotus), for commercialising its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.
Ryaltris is a novel, fixed-dose combination nasal spray of an anti-histamine (olopatadine hydrochloride) and a steroid (mometasone furoate), indicated for the treatment of symptoms associated with allergic rhinitis (AR) in adults and paediatric patients, 12 years of age and older.
Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris, whereas Lotus will be responsible for the commercialisation of Ryaltris (subject to receipt of regulatory approvals), in these markets.
Glenmark will receive an upfront payment as well as regulatory and sales-based milestone payments from Lotus.
“We are excited to partner with Lotus for Ryaltris as it is a strong and reputed player in the region and is aligned with Glenmark’s objective to provide quality novel products to fulfil unmet needs of patients with allergic rhinitis. This partnership will provide patients access to a highly effective and proven treatment for allergic rhinitis in these key South-East Asian markets,” said Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals Ltd.
“As being strongly committed to making a difference for all patients, we are honoured to partner with Glenmark to ensure this novel spray drug is accessible to patients in South East Asia. This is also the first Brand product to be included in our respiratory portfolio with strong clinical data and IP protection,” Petar Vazharov, Chief Executive Officer of Lotus said.
“The partnership not only strengthens the competitiveness of our overall product portfolio but also accelerates our expansion in key SEA countries,” Vazharov added.
Allergic rhinitis (AR) is a highly prevailing yet underdiagnosed heterogeneous disorder that is characterized by one or more symptoms including sneezing, itching, nasal congestion, and rhinorrhea and contributes to missed or unproductive time at work, sleep problems and decreased involvement in outdoor activities around the world. The prevalence of AR is 4.2% in Hong Kong, 4.9% in Singapore and 12.3% in Vietnam.
Severity: Warning
Message: mysqli::query(): (HY000/1): Can't create/write to file '/tmp/#sql_3cd_0.MYI' (Errcode: 28 - No space left on device)
Filename: mysqli/mysqli_driver.php
Line Number: 307
Backtrace:
File: /home/drugtodayonline/public_html/application/models/Site_ads_model.php
Line: 118
Function: query
File: /home/drugtodayonline/public_html/application/libraries/Common_lib.php
Line: 318
Function: get_front_ads_data
File: /home/drugtodayonline/public_html/application/views/front/news_topic.php
Line: 332
Function: common_footer_ads
File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 361
Function: view
File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 28
Function: news_topic
File: /home/drugtodayonline/public_html/index.php
Line: 311
Function: require_once
Severity: Warning
Message: Cannot modify header information - headers already sent by (output started at /home/drugtodayonline/public_html/system/core/Exceptions.php:271)
Filename: core/Common.php
Line Number: 570
Backtrace:
File: /home/drugtodayonline/public_html/application/models/Site_ads_model.php
Line: 118
Function: query
File: /home/drugtodayonline/public_html/application/libraries/Common_lib.php
Line: 318
Function: get_front_ads_data
File: /home/drugtodayonline/public_html/application/views/front/news_topic.php
Line: 332
Function: common_footer_ads
File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 361
Function: view
File: /home/drugtodayonline/public_html/application/controllers/Medical_news.php
Line: 28
Function: news_topic
File: /home/drugtodayonline/public_html/index.php
Line: 311
Function: require_once
Error Number: 1
Can't create/write to file '/tmp/#sql_3cd_0.MYI' (Errcode: 28 - No space left on device)
SELECT * FROM `dt_site_ads` WHERE `status` = '1' and `loc` = 'pre_footer_4' ORDER BY RAND() LIMIT 0,1
Filename: models/Site_ads_model.php
Line Number: 118
